All of these groups of compounds are covered by Provectus' joint patent application with Pfizer for the combination of PV-10 and other therapies. All of the above drugs have been combined with PV-10 by Moffitt.
May 30, 2013
ASCO 2013 Immunotherapy Highlights Covered by $PVCT-$PFE's Combination Therapy Patent Application
Sally Church, writer of the Pharma Strategy Blog, notes ASCO 2013 will bring new data on immunotherapy agents called checkpoint regulatory inhibitors.
All of these groups of compounds are covered by Provectus' joint patent application with Pfizer for the combination of PV-10 and other therapies. All of the above drugs have been combined with PV-10 by Moffitt.
All of these groups of compounds are covered by Provectus' joint patent application with Pfizer for the combination of PV-10 and other therapies. All of the above drugs have been combined with PV-10 by Moffitt.
No comments:
Post a Comment